Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration (FDA) raised no objections to proposed protocol amendments for the ongoing Phase 2 HARMONIC trial evaluating LP-300 in never-smokers with advanced non-small cell lung cancer (NSCLC) adenocarcinoma. The FDA's written response to the company's Type C meeting request provides a clearer regulatory path forward for the program, including a strategy focused on the EGFR exon 21 L858R-mutant never-smoker population, where emerging data suggest LP-300 may offer differentiated benefit in combination with standard chemotherapy following kinase inhibitor treatment failure.
The HARMONIC trial is a randomized, double-blind, placebo-controlled Phase 2 study assessing LP-300 in combination with standard chemotherapy versus chemotherapy alone in never-smoker patients with relapsed advanced lung adenocarcinoma after tyrosine kinase inhibitor (TKI) treatment. The FDA's support for the amendments could streamline the development of LP-300, a cisplatin/ethacraplatin analog, potentially addressing an unmet need in this specific patient subgroup. Never-smokers with NSCLC often have distinct molecular profiles, including EGFR mutations, and may respond differently to therapies compared to smokers.
This news is significant for the lung cancer community, as it highlights a precision oncology approach targeting a genetically defined population. For patients with EGFR exon 21 L858R mutations who have progressed on TKIs, treatment options are limited. LP-300's combination with chemotherapy may provide a new therapeutic avenue. The regulatory clarity from the FDA de-risks the program and accelerates its clinical development, which could impact clinical practice if the trial proves successful.
Lantern Pharma is a clinical-stage precision oncology company leveraging artificial intelligence and machine learning through its proprietary RADR platform to transform cancer therapy development. The company's pipeline includes LP-184, LP-284, and LP-300. Additionally, Lantern's withZeta.ai platform, a multi-agentic AI co-scientist, is now commercially available as a subscription-based research platform, representing a new revenue stream. Lantern operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.
For more information, visit the company's newsroom at https://ibn.fm/LTRN. The full press release is available at https://ibn.fm/Rxklm.
